MetaCap

Regencell Bioscience Holdings Limited (RGC)

NASDAQ: RGCHealth Care Medicinal Chemicals and Botanical Products USD

4.18-0.18 (-4.13%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

RGC stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.02
52-week range
4.12 – 69.00
Day range
4.12 – 4.43
Volume / Avg
110.89K / 234.51K
Beta
—

52-week range

$4.12$69.00

RGC stock today

Shares of Regencell Bioscience (RGC) finished lower on Nov 20 at $4.18, a drop of 4.13% or $0.18 per share, versus the S&P 500's 3.70% decline. Trading was light, with 110.89K shares changing hands, about 47% of the average daily volume. At this level, RGC sits near the bottom of its 52-week range of $4.12 to $69.00: 93.9% below the high, set on Jan 8, 2026 and 1.5% above the low.

RGC is down 80.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 66.5%. Regencell Bioscience has posted a net loss over the last twelve months (EPS of -$0.02), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Regencell Bioscience

Company profile

Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, TCM brain theory, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Industry
Medicinal Chemicals and Botanical Products
CEO
Mr. Yat-Gai Au
Headquarters
Causeway Bay
Employees
10
IPO year
2021

Financial highlights

Full financials

Regencell Bioscience reported a net loss of $11.7 million, compared with a loss of $3.6 million a year earlier. Diluted earnings per share came in at -$2.37.

Regencell Bioscience annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022
Revenue—————
Growth—————
Net income$-11.70M$-3.58M$-4.30M$-5.87M$-7.45M
EPS (diluted)$-2.37$-0.72$-0.87$-1.19$-0.58

RGC news

All RGC news

Regencell Bioscience peers

Health Care sector
RGC peer companies
CompanyPrice% ChgMarket capCompare
TRLVTrulieve Cannabis Corp. Subordinate Voting Shares8.68-7.17%$1.48Bvs RGC
CRONCronos Group Inc.3.04-1.30%$1.11Bvs RGC
OBIOOrchestra BioMed Holdings Inc.6.58-6.00%$517.88Mvs RGC
SNDLSNDL Inc.1.17-5.65%$285.20Mvs RGC
TLRYTilray Brands Inc.1.89-8.70%$279.32Mvs RGC
ACBAurora Cannabis Inc.4.16-2.35%$273.50Mvs RGC
DFTXDefinium Therapeutics Inc.28.34-3.87%$3.88Bvs RGC
USNAUSANA Health Sciences Inc.12.94-1.67%$239.24Mvs RGC

Indexes, lists and sector

Regencell Bioscience stock FAQ

What is Regencell Bioscience's stock price today?

RGC last traded at $4.18 as of Nov 20, 4:00 PM EST, down 4.13% on the day. Prices are delayed at least 15 minutes.

Does Regencell Bioscience pay a dividend?

No. Regencell Bioscience does not currently pay a regular cash dividend.

Who is Regencell Bioscience's CEO?

Mr. Yat-Gai Au is the chief executive officer of Regencell Bioscience Holdings Limited, which has about 10 employees.

Has RGC ever split its stock?

Yes. The most recent RGC stock split was a 38-for-1 split on Jun 16, 2025.

What is the RGC 52-week high?

The 52-week high for RGC is $69.00 and the 52-week low is $4.12. The stock is currently 93.9% below its high.

Compare RGC